Suven life sciences secures four new drug molecule patents in four countries
The Hyderabad-based Suven Life Sciences received patents in four countries for the new drug molecules.
Ahmedabad, August 9, 2012: In a recent development, Suven Life Sciences has received four product patents, one each from countries like Australia, Canada, Korea and New Zealand for the new drug molecules.
The drug molecules are generally used to treat the disorder related to the Neuro-degenerative diseases. For the less informed, Neuro-degenerative disease is a broad term for a range of conditions which affect the neurons in a human brain. Diseases like Parkinson, Alzheimer and Huntington may occur due to the Neuro-degenerative process.
The Hyderabad-based company has received four product patents from four countries and these patents will remain valid through 2028, it said in a filing to the Bombay Stock Exchange (BSE). The company further said that the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
It is worth noting here that the company has twelve (12) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.
Taking into account the latest patents, the company now holds a total of 15 from Australia, 9 from Canada, 8 from Korea and 13 granted patents from New Zealand.